The National Stock Exchange of India Ltd. (NSE) sent an email to Dr. Reddy's on November 3, 2026 (Reference: NSE/CM/Surveillance/17766).
The query sought clarification regarding a news article published on November 3, 2026, on the website First Post, with the headline: "India's Dr Reddy's gets US nod for $40 generic HIV prevention shot for 120 poorer countries".
Company’s Clarification on News and Trading
The company confirmed the news headline is correct.
The news pertained to the company's own press release dated November 2, 2026, titled: "U.S. FDA grants tentative approval for Dr. Reddy's twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US."
The company stated that no negotiations were involved, making that part of the query not applicable.
The company clarified it is not aware of any undisclosed information that could explain any movement in trading, reaffirming that no material event required disclosure.
Details of Financial Impact
The company explicitly stated: "We believe that there is no material impact of the above referred news article on the Company."
